The most recent estimate of the Exubera (inhaled insulin) rollout has been delayed again, this time until January 2007, according to a Pfizer report. The company cites manufacturing issues in the scale-up process as the cause of the delay. This news follows speculation by some that the product may not become the blockbuster as originally touted, including a report in Business Week that cited Exubera's clunky, large-sized inhaler and required periodic lung function tests as reasons for doubt.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.